| Title: |
Childhood, Adolescent and Young Adult Poor-Prognosis Rhabdomyosarcoma |
| Authors: |
Ajla T. Wasti; Gianni Bisogno; Raquel Hladun; Anne-Sophie Defachelles; Michela Casanova; Willemijn B. Breunis; Susanne A. Gatz; Reineke A. Schoot; Andrea Ferrari; Meriel Jenney; Rita Alaggio; Raquel Davila Fajardo; Sheila Terwisscha van Scheltinga; Janet Shipley; Michael Torsten Meister; Rick R. van Rijn; John Anderson; Monika Sparber-Sauer; Julia C. Chisholm; Johannes H. M. Merks |
| Source: |
Cancers ; Volume 17 ; Issue 19 ; Pages: 3100 |
| Publisher Information: |
Multidisciplinary Digital Publishing Institute |
| Publication Year: |
2025 |
| Collection: |
MDPI Open Access Publishing |
| Subject Terms: |
rhabdomyosarcoma; metastatic; relapse; child; adolescent; young adult; chemotherapy; radiotherapy; surgery; novel approaches |
| Description: |
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and young people. Despite the advances in multimodality treatment over recent decades through successive prospective clinical trials, improved rates of survival for patients are mainly limited to those with localised RMS without adverse biologic features. Current clinicopathologic prognostic factors include PAX3(7)::FOXO1 fusion status, the site of primary disease, the pre-chemotherapy extent of disease (including microscopic vs. macroscopic residual disease, locoregional nodal involvement and metastatic status), tumour size and patient age. These factors are used to stratify patients into prognostic risk groups that guide treatment intensity and duration. Risk stratification algorithms are evolving, supported by advances in molecular biology and cancer genomics. In this review we focus on the poorest prognostic groups of paediatric-type RMS (i.e., Very High Risk or relapsed/progressive disease). These include patients whose tumours harbour poor biological characteristics such as PAX3(7)::FOXO1 fusion-positive tumours with locoregional nodal involvement and tumours harbouring other poor-risk genetic variants (particularly MYOD1 and TP53 variants); adolescent and young adult patients; newly diagnosed patients with metastatic RMS; and patients with relapsed and refractory disease. Here we aim to describe the clinical characteristics of these patients, outline current standard multimodality treatments in the context of sequential international clinical trials across the major cooperative groups and summarise emerging novel diagnostic and therapeutic approaches. |
| Document Type: |
text |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
Pediatric Oncology; https://dx.doi.org/10.3390/cancers17193100 |
| DOI: |
10.3390/cancers17193100 |
| Availability: |
https://doi.org/10.3390/cancers17193100 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.5D3B5B20 |
| Database: |
BASE |